<DOC>
	<DOCNO>NCT01005641</DOCNO>
	<brief_summary>Aromatase inhibitor standard treatment hormone responsive advance breast cancer . The combination aromatase inhibitor exemestane another breast cancer drug block epidermal growth factor receptor ( EGFR ) Erb-2 activity ( lapatinib ) study possibility improve response therapy , delay resistance endocrine therapy .</brief_summary>
	<brief_title>ELBA : Exemestane Lapatinib Advanced Breast Cancer</brief_title>
	<detailed_description>The recommend dose lapatinib determine first part study . In second part study , patient receive recommend dose lapatinib exemestane daily , take orally .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Histological diagnosis breast cancer Indication hormonal therapy ( ER and/or PgR positive ) Stage IV disease Female gender Postmenopausal status ( patient treat LHRH analog eligible Phase II part study ) At least one target nontarget lesion accord RECIST criterion ECOG Performance Status 02 Adequate bone marrow ( neutrophils &gt; = 1.500/mm³ , platelet &gt; = 100.000/mm³ hemoglobin &gt; = 9 g/dl ) , hepatic ( GOT , GPT &lt; 2.5 e bilirubin &lt; 1.25 time value upper normal limit ) renal ( creatinine &lt; 1.25 time value upper normal limit ) function Adequate cardiac function ( FEVS &gt; = 50 % ) Able take oral medication Life expectancy &gt; 3 month Signed informed consent Any previous hormone therapy metastatic disease More one line chemotherapy metastatic disease ( first line chemotherapy permit ) Symptomatic cerebral metastasis Planned concomitant radiation therapy first month therapy ( patient participate dose find phase study ) Previous therapy exemestane , include adjuvant therapy ( previous therapy nonsteroidal aromatase inhibitor permit ) Previous concurrent malignancy past 5 year ( exclude adequately treat basal cel spinocellular skin cancer situ carcinoma cervix ) Treatment experimental pharmacologic therapy within 4 week enrollment study Unable unwilling provide sign informed consent Any concurrent illness would , Investigator 's opinion , contraindicate use study drug . Active infection Assumption CYP3A4 inhibitor inducer ( ketoconazole , itraconazole , fluconazole , macrolide antibiotic , antidepressives , calciumantagonists , cimetidine , carbamazepine , phenytoin , barbiturate , rifampicin e glucocorticoid ) Pregnancy lactation Unable comply followup Active hepatobiliary disease ( exception Gilbert 's syndrome , asymptomatic biliary calculus , hepatic metastasis stabile chronic hepatopathy )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>advanced breast cancer</keyword>
	<keyword>hormone-responsive</keyword>
	<keyword>metastatic breast cancer</keyword>
</DOC>